KBP-5074

DRUG7 trials

Sponsors

KBP Biosciences

Conditions

Chronic Kidney DiseaseChronic Kidney DiseasesDrug Drug InteractionHealthyModerate Hepatic ImpairmentRenal Insufficiency

Phase 1

Phase 1 Single Ascending Dose Study to Evaluate Safety, Tolerability and Pharmacokinetics of KBP-5074

CompletedNCT02228733

KBP BiosciencesHealthy

Start: 2014-06-30End: 2015-01-31Updated: 2025-12-16

Safety, Tolerability and Pharmacokinetics of KBP-5074 in Healthy Subjects and Subjects With Renal Impairment

CompletedNCT02653014

KBP BiosciencesHealthy, Renal Insufficiency

Start: 2015-07-29End: 2017-03-28Updated: 2025-12-16

Safety, Tolerability, and Pharmacokinetics of KBP-5074 Following Oral Administration in Chronic Kidney Disease

CompletedNCT02837237

KBP BiosciencesChronic Kidney Disease

Start: 2016-07-13End: 2017-06-30Updated: 2025-12-30

Pharmacokinetics of KBP-5074 in Patients With Moderate Hepatic Impairment

CompletedNCT04534699

KBP BiosciencesHealthy, Moderate Hepatic Impairment

Start: 2020-08-27End: 2020-11-19Updated: 2025-12-16

Drug to Drug Interaction Study of KBP-5074 in Healthy Subjects

CompletedNCT04606537

KBP BiosciencesDrug Drug Interaction, Healthy

Start: 2020-10-24End: 2020-11-30Updated: 2025-12-16

Mass Balance Study of KBP-5074 in Healthy Male Subjects

CompletedNCT04634812

KBP BiosciencesHealthy

Start: 2020-12-03End: 2020-12-23Updated: 2025-12-16

Phase 3

Efficacy and Safety of KBP-5074 in Uncontrolled Hypertension and Moderate or Severe Chronic Kidney Disease (CKD)

TerminatedNCT04968184

KBP BiosciencesChronic Kidney Diseases

Start: 2021-11-05End: 2024-07-10Updated: 2025-09-03

Related Papers

Pharmacokinetics of the Novel Nonsteroidal Mineralocorticoid Receptor Antagonist Ocedurenone (KBP-5074) in Individuals with Moderate Hepatic Impairment.

2024-02-081 citations